The Pivotal Role of Proteasome Inhibition in Myeloma Treatment

This symposium took place on 26th March 2017, as a part of the European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting in Marseille, France

Chairperson: Meletios Dimopoulos1
Speakers: Nikhil C. Munshi,2 Pieter Sonneveld3

1. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2. Harvard Medical School; Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Disclosure: Prof Dimopoulos has received honoraria and consulting fees from Amgen, Genesis, Celgene, Janssen, Novartis, and Takeda Pharmaceuticals International AG, and has served as an advisory board member for Amgen, Celgene, Janssen, Novartis, and Takeda Pharmaceuticals International AG. Prof Munshi has received honoraria for consulting from Takeda Pharmaceuticals International AG, Celgene, Novartis, Merck, Pfizer, and Janssen, and is a scientific founder of OncoPep. Prof Sonneveld has received honoraria for consulting from Janssen, Amgen, Karyopharm, and Takeda Pharmaceuticals International AG, has received honoraria from Celgene, Janssen, Amgen, Karyopharm, and Takeda Pharmaceuticals International AG, and has received research funding from Celgene, Janssen, Amgen, and Karyopharm.
Acknowledgements: Writing assistance was provided by Mia Cahill, ApotheCom, London, UK.
Support: The publication of this article was funded by and reviewed by Takeda Pharmaceuticals International AG.
Citation: EMJ Hematol. 2017;5[Suppl 9]:2-10.

Meeting Summary

The main objectives of this symposium were to explore new insights into the biology of multiple myeloma (MM) in the context of new treatment options, discuss the clinical evidence supporting continuous therapy (CT) as a means of enhancing autologous stem cell transplant (ASCT) outcomes, and explore the modern treatment options for patients with relapsed/refractory MM (RRMM), including proteasome inhibitors (PI). Prof Nikhil C. Munshi introduced the latest research on the biology of MM and its possible translation to the clinic and treatment decisions. Prof Pieter Sonneveld then discussed the current clinical knowledge and evidence for the relative roles of ASCT and CT in treating MM in the context of three clinical questions, with expert panel perspectives on each question. Prof Meletios Dimopoulos closed the symposium with an in-depth look at treatment options for RRMM and the results of the TOURMALINE-MM1 trial. Clinical case studies added relevance to these key learnings and demonstrated the importance of a holistic approach to treatment.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Download (PDF, 166KB)

Comments are closed.